We retrospectively studied patients with cIA NSCLC who underwent pulmonary resection (at least lobectomy) and extensive lymphadenectomy (more than ND2a-1) at our institution between January 2004 and December 2010. We investigated the following factors for their association with SN2: age; sex; tumour marker (carcinoembryonic antigen); tumour size on computed tomography (CT), evaluated with a lung-window (LW) and a mediastinal-window (MW) setting; pathology, with or without adenocarcinoma; differentiation; visceral pleural invasion (VPI) and vascular/lymphatic invasion.
INTRODUCTION
Skip N2 metastasis (SN2) is pathologically defined as mediastinal lymph node involvement ( pN2) without hilar lymph node ( pN1). SN2 occurs in approximately 17.2-42.3% of N2 patients with non-small-cell lung cancer (NSCLC) ( Table 1 ) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . NSCLC with pN2 status has a generally poor survival, but the prognosis is more favourable among patients with SN2 when compared with continuous pN2 lesions [2, 5, 7, 8, 10] . Although selecting patients with SN2 is important for improving prognosis, little is known of either the clinicopathological features or the mechanism of SN2. In addition, it remains unclear whether extensive mediastinal lymphadenectomy is effective for patients with SN2.
Some authors have referred to this subpleural lymphatic drainage system as the main mechanism of SN2 [8, 16, 17] . The lymphatic system of the lung is classified into superficial and deep lymphatic vessels, with the latter vessels usually ending in bronchopulmonary lymph nodes; conversely, the former comprises capillary nets of subpleural lymphatic vessels and subpleural collecting lymphatic vessels [16, 17] . It is suggested that the draining of these subpleural lymphatics directly to the mediastinum is the most influential mechanism for SN2 [8, 10, 13, 14] . Imai et al. [18] investigated the subpleural lymphatic flow to the mediastinum using indocyanine green and confirmed that the rate of direct lymphatic flow to the mediastinum was 21.4%, which was compatible with the established range of SN2.
In contrast with the large number of reports seeking to elucidate the mechanism of SN2, few have considered the type of patient most likely to benefit from radical lymphadenectomy. For example, patients with earlier disease, poorer pulmonary function and older age are likely to require only lymph node sampling. Therefore, it is important to know the clinicopathological features of patients with SN2 in NSCLC to facilitate surgical planning and treatment. This study aimed to investigate patients with clinical stage IA (cIA) NSCLC to determine the characteristic features associated with SN2.
PATIENTS AND METHODS
We retrospectively studied patients with cIA NSCLC who had not received preoperative chemoradiotherapy. All patients underwent pulmonary resection (at least lobectomy) and extensive lymphadenectomy (more than ND2a-1) at our institution between January 2004 and December 2010. The following definitions were used: tumours were staged according to the TNM classification [19] ; pathological examination was based on the 2004 WHO classification [20] ; SN2 was defined as pathologically verified pN2 without pN1, i.e. N1[−]N2 [+] ; and the lymph node location was based on that established by the Committee of the International Union against Cancer [21] .
We investigated the following factors for their association with SN2: age, sex; carcinoembryonic antigen (CEA) tumour marker; tumour size via lung-window {[LW; level −500 Hounsfield Unit (HU), width 1500 HU}] and mediastinal-window (MW; level 60 HU, width 350 HU) computed tomography (CT) settings; histological type, i.e. adenocarcinoma (ADC) or non-ADC; histological differentiation (HD); visceral pleural invasion (VPI), Grade 0-2 and vascular (v) and/or lymphatic invasion (Ly).
Statistical analysis
All data were analysed using the SPSS software (version 17.0, SPSS Institute Incorporated, Chicago, IL, USA). Sensitivity and specificity were compared using standard formulae. Differences between two groups were assessed using the Mann-Whitney U-test.
Comparison among three or more groups was determined by the Kruskal-Wallis test. Multivariate analyses were performed using the logistic regression model for variables with significant differences after univariate analyses. Statistical significance was considered to be achieved with P < 0.05.
RESULTS

Descriptive statistics for patients with skip metastasis
The patient characteristics are summarized in Skip metastasis and tumour size on preoperative computed tomography
We verified which evaluation system on high resolution computed tomography was superior for patients with cIA NSCLC and the appropriate size for a diagnosis of SN2 via LW and MW. In patients with NSCLC, SN2 was found in 23.8% (5/21) of patients with sizes <20 mm ( pT1a) via LW (176; 41.7%), but was not found in those with a tumour diameter of <10 mm via MW (n = 150; 35.5%).
As shown in Fig. 1 , the areas under the receiver operating characteristic curves (AUC) were 0.74 and 0.67 for MW and LW, respectively. When the AUC cut-off level was defined as a MW of 11.5 mm and an LW of 24.5 mm using the Youden index, SN2 had respective sensitivities and specificities of 95.2 and 42.9% for MW, and 61.9 and 64.3% for LW.
Skip metastasis pattern according to tumour location
The frequency of SN2 according to lobe involvement is summarized in Table 3 . SN2 was found predominantly in patients with left upper lobe tumours, but the difference was not significant (P = 0.49). In addition, SN2 was not significantly more frequent in the upper lobe (15/246; 6.1%) than in the lower lobe (5/138; 3.6%) (P = 0.37). In the upper lobe, SN2 metastasis was pathologically diagnosed in nodes in the following locations: 7 (46.7%) right upper mediastinal zone (Nodes 1-4), 6 (40.0%) left aortopulmonary window (APW; Nodes 5 and 6) and in 2 (13.3%) right lower mediastinal zone (LMZ; Nodes 7-9). In contrast, all SN2 in the lower lobe were in the LMZ.
The predictive factor of skip metastasis in clinical stage IA non-small-cell lung cancer
We evaluated the predictive factor of SN2 in patients with cIA NSCLC. As shown in Table 4 , the following were significantly correlated with SN2: male, CEA (>5 ng/ml), tumour size in both LW Figure 1 : Receiver operating characteristic curves for the lung-window (solid line) and mediastinal-window (dotted line) settings were derived by plotting the relationship between the sensitivity and the specificity for detecting skip N2 metastases at various cut-off levels. (>24.5 mm) and MW (>11.5), HD, VPI (1-2) and v(+) and/or Ly(+).
No other factor showed significant association by univariate analysis. Multivariate analysis showed that only VPI (1-2) was a significant factor (Table 5 ).
The predictive factor of skip metastasis in lymph node-positive patients
Among patients with nodal metastases (n = 91), we explored the factors accounting for the difference between the groups with and without SN2. Univariate analysis revealed that only VPI (1-2) had a significant association (P < 0.01; Table 6 ). The multivariate analysis yielded a similar result with VPI (1-2) as an independent factor (P = 0.04, hazard ratio = 3.69; Table 7 ). Next, we analysed the impact of VPI subtype. In patients with nodal involvement, the VPI classification comprised 59 PL-0 (64.8%), 12 PL-1 (13.2%) and 20 PL-2 (22.0%); of which, the VPI population was 15.3% (9/59), 3/12 (25%) and 9/20(45%), respectively. The difference between the three groups was significant (P = 0.03), but that between VPI 1 and 2 was not (P = 0.27).
DISCUSSION
Over the past three decades, many authors have considered the mechanisms of SN2 (Table 1) . Three significant, but controversial factors for SN2 have been reported: tumour location, histological type and tumour size [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Previous reports have also reported three mechanisms of SN2 metastasis as being anatomical lymphatic flow, micro-metastasis and biological behaviour [8, 22, 23] . In this retrospective study, we postulated that SN2 was significantly associated with VPI in patients with cIA NSCLC, and that our result may be caused by the first of these latter mechanisms, despite not investigating the other mechanisms. To the best of our knowledge, this is a first report about the association between VPI and SN2 in patients with cIA NSCLC. The frequency of SN2 gradually and significantly decreased over these periods (P < 0.01); it was significantly higher in the 1980s (35.6%) than in the 1990s (27.8%) (P < 0.01) and was significantly higher in the 1990s than in the 2000s (23.2%) (P = 0.04). Li et al. [14] analysed this variation of the different reports concerning the rates of SN2 and suggested that this may have been due to missed diagnoses of hilar lymph nodes. We also conjecture that technological improvements increasing the likelihood of diagnosing hilar lymph nodes have contributed to this phenomenon. In our present study, the frequency of SN2 (40.4%) was similar to that reported by Takizawa et al. in the 1980s [3] . However, both these reports and our study only evaluated SN2 in patients with cIA. Two studies have reported the association between pleural involvement and SN2, but no significant differences were found in either case [8, 14] . The limitation of cIA in our study may explain the differences to these previous results. The lymphatic drainage system of the lungs has been studied for a long time. Riquet et al. [17] reported that 23.6% of segmental lymph channels drained directly into mediastinal nodes in 260 cadavers, and there was a high frequency of single or dual station N2 involvement [8] . They commented that this may be due to desquamating tumour cells within the pleural space, which are reabsorbed by lymphatic vessels of the parietal and diaphragmatic pleura, thereby theoretically inducing SN2, but failed to demonstrate a significant association (n = 209; pN2) [8] . However, in our explanation, the incidence of SN2 is significantly associated with pleural involvement in patients with cIA and in those with nodal metastases. In the present study, we propose that VPI was a key factor in SN2, and assume an involvement of the subpleural lymphatic network. A conceivable scenario is a cancer located at the periphery of the lung, which is growing towards the visceral pleura and into the lymphatic ducts below the visceral pleura, and metastasizing to the mediastinal lymph nodes. Our study was small, however, necessitating further investigation; nonetheless, we did evaluate pleural involvement in all suspicious cases via Elastica van Gieson dyeing.
A review has described that tumour histology and tumour location are the two tumour attributes most commonly described as suspected of contributing to the incidence of SN2 [23] . Several arguments currently exist whether both these factors relate to SN2, and a definitive conclusion is yet to be obtained. Furthermore, SN2 has been found more frequently among ADC than squamous cell carcinoma [23] . Ilic et al. [11] reported that the opposite was true, with a higher incidence of SN2 in squamous cell carcinoma, despite the fact that overall nodal involvement was greater in patients with ADC. They concluded that nodal spread in ADC was continuous along lymphatic drainage pathways. To confound matters, some authors have failed to find any significant correlation between the two pathologies [1, 2, 5, 8, 14] . In our study, histological type (ADC or non-ADC) was not a significant factor in patients either with cIA or with nodal metastasis.
Both of the upper lobe lesions have been reported to skip metastasize to superior mediastinal stations most commonly [23] . Riquet's report concerning the direct anatomical drainage pattern of lymph into mediastinal lymph nodes is generally quoted to explain this phenomenon [8, 17] . On the other hand, some adverse results have been reported. Misthos et al. [7] reported that SN2 was strongly related to primary lesion of the right lower lobe although not statistically significant. Some authors also reported no significant correlation between SN2 and tumour location [2, 11] . While these findings are indeed recognized, Ito et al. [13] have found that the distance between the tumour and metastatic lymph node was important in patients with skip metastasis. In our study, the SN2 primary tumour location was found predominantly in the left upper lobe, but without significance. In addition, SN2 was not significantly more frequent in any particular lobe or laterality. Further study is necessary to clarify these issues.
Some articles have reported that tumour size and advanced stage were significantly associated with the incidence of SN2 [8, 10, 14] . In our study, SN2 was significantly associated with both LW and MW cut-offs based on the AUC for patients with cIA, but not in those with nodal metastasis. We previously reported the correlation between MW and lymph node involvement, where the incidence was higher in the larger size subgroups in patients with cT1 (≤10 mm: 6.7%, 11-20 mm: 16.7% and 21-30 mm: 28.6%) [24] . In addition, <5 mm on MW could represent no pleural involvement and no lymphatic or vascular invasion [25] . All patients with SN2 were >10 mm via MW. Although MW (>11.5 mm) had a low specificity in the assessment of SN2, it had a high sensitivity, suggesting the possibility of a superior benefit compared with LW. We suggest that an accurate understanding of the invasive capacity on increases in tumour size using MW reduced the risk of missing SN2 metastasis through the subpleural lymphatic channel.
Lobectomy plus lymphadenectomy (more than ND2a-1) is the standard procedure for cIA NSCLC. However, various surgical procedures have recently been developed, including wedge resection, anatomical segmentectomy and selective mediastinal lymph node dissection. These limited surgical procedures pose a risk in cIA NSCLC because they may be insufficient to manage the risk of SN2, which may be overlooked. Based on our results, the radiological criteria for NSCLC should employ the MW cut-off value of 11.5 mm. Although the correct assessment of radiological or operative VPI findings was sometimes difficult in clinical experience, preoperative or intraoperative suspicions of VPI were often valid in predicting pathological SN2.
In conclusion, this study suggests that the incidence of SN2 was significantly associated with VPI in patients with cIA NSCLC and in those with nodal metastases. Although MW (>11.5 mm) had a low specificity in the assessment of SN2, it had a high sensitivity, suggesting the possibility of a superior benefit compared with LW. We encourage the use of lobectomy with lymphadenectomy for cIA NSCLC rather than limited surgical procedures. This can be selected based on preoperative or intraoperative suspicions of pleural involvement and a radiological maximum tumour diameter of >11.5 mm via a MW on thin-slice CT because these are associated with SN2. Standard hilar and mediastinal lymph node dissection should be required in those patients.
